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Abstract 
Review on SERPINB3, with data on DNA/RNA, 
on the protein encoded and where the gene is 
implicated. 
Identity 
Other names: HsT1196, SCC, SCCA-1, SCCA-
PD, SCCA1, T4-A 
HGNC (Hugo): SERPINB3 
Location: 18q21.33 
Local order: According to Entrez-Gene, 
SERPINB3 maps to NC_000018.10 in the region 
between 63655197 and 63661963, complement and 




SERPINB3, also known as SCCA1, encodes 
members of the serpins family. The serpins are a 
family of protease inhibitors originally grouped 
together as serine protease inhibitors, most of which 
are secreted (Silverman et al., 2004). The clade B 
serpins comprise a number of proteins including 
SERPINB3. In the early 1990's (Takeshima et al., 
1992) it was recognized as circulating "squamous 
cell carcinoma antigen" (SCCA1) that was present 
in a substantial fraction of sera from patients 
bearing squamous cell cancers of the cervix. Later 
on it was found to be associated with other types of 
cancer of epithelial or endodermal origins, 
including lung cancer, head and neck cancer, and 
hepatocellular carcinoma (Schneider et al., 1995; 
Pontisso et al., 2004). 
 
 
Figure 1. A. SERPINB3 maps in chromosome 18q21.3 (NC_000018.10) in the region between 63655197 and 63661963. Local 
order and flanked genes are reported. B. Map of a SERPINB3 transcript mRNA (NM_006919.2) showing its organization in 8 
exon. 
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Figure 2. SERPINB3 protein mature chain. Site of Reactive Center Loop (RSL) (blue), and described variants (green) are 




According to the NCBI map viewer, the gene is 
located on chromosome 18q21.3 (NCBI Reference 
Sequence: NC_000018.10) and encompasses 6767 
bp. 
Transcription 
The SERPINB3 gene comprises eight exons and 
seven introns which commonly encoded a 1,793 kb 
mRNA. The ATG start is located in exon 2 with the 
stop codon in exon 8. 
Transcription control is regulated by STAT3. 
STAT3 occupies the promoter of SERPINB3/B4 
and siRNA removal of SERPINB3/B4 mRNA 
caused cell death in HN13 head and neck cancer 
cells. Thus persistently activated STAT3 is a 
required part of the continuous activation of 
SERPINB3/B4 genes, which protects tumor cells 
from dying (Ahmed and Darnell, 2009). 
Moreover recent mechanistic experiments and ChIP 
assays reveal that SERPINB3 increased expression 
in response to hypoxic conditions is specifically 
mediated by the binding of HIF-2α to the 
SERPINB3 promoter (Cannito et al., 2013). 
Pseudogene 
No known pseudogene. 
Protein 
Description 
SERPINB3 encodes a 390 amino acid 44,56 Kda 
protein, which shows sequence homology to the 
ovalbumin family of serine protease inhibitors (Ov-
serpin) (Remold-O'Donnell, 1993), a subfamily of 
the large serpin superfamily. Serpins have a highly 
ordered tertiary structure defined by the crystal 
structure of the prototype molecule α1-antitrypsin, 
consisting of nine α-helices and three β-sheets 
arranged in a stressed configuration with the 
reactive center, which has the unusual feature of 
being the most variable region, located in an 
exposed loop (Hunt and Dayhoff, 1980). 
The mechanism of protease inhibition by serpins 
involves a profound change in conformation, 
initiated by interaction of the protease with the 
reactive site loop of the serpin (RSL) (amino acids 
340-368). RSL consists of a loop projecting from 
the body of the protein, comprising a hinge region 
and a variable RSL (Huntington et al., 2000). 
Biochemical analysis of recombinant SERPINB3 
shows that it is a potent cross-class inhibitor of 
papain-like cysteine proteinases such as cathepsin 
L, cathepsin S and cathepsin K (Schick et al., 
1998). 
An isoform produced by alternative splicing has 
been reported. The sequence of this isoform differs 
from the canonical sequence for 205-256 amino 
acid missing (Fig.2). 
Expression 
SERPINB3 is expressed in the spinous and granular 
layers of normal squamous epithelium, in several 
organs including: epithelium of the tongue, 
esophagus, tonsil, cervix uterine, vagina, Hassal's 
corpuscles of the thymus and some areas of the 
skin. SERPINB3 was also detected in saliva, 
respiratory secretions and amniotic fluid samples 
from healthy individuals (Kato, 1996; Cataltepe et 
al., 2000). Moreover, SERPINB3 was recently 
reported to be expressed on CD27+ B lymphocytes 
(Vidalino et al., 2012). 
In particular, immunohistochemistry analysis 
revealed positive staining in sweat glands in the 
dermis of the skin, endothelial cells of the veins and 
arteries walls in the intestine. 
Within the normal liver, SERPINB3 protein 
expression was seen in portal interlobular ducts, in 
the walls (myocytes of the media) of the large and 
medium sized hepatic arteries and sometimes in the 
endothelial cells of the portal veins. 
Normal hepatocytes, sinusoidal cells and Kupffer 
cells do not exhibit any reactivity, except some 
hepatocytes in the limiting plate that can show focal 
faint positivity (Turato et al., 2012). 
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HepCAM positive liver stem cells from both foetal 
and adult livers also express SERPINB3 (Villano et 
al., 2014). 
Initially, SERPINB3 was discovered as a 
serological marker for advanced squamous cell 
tumors in the cervix (Uemura et al., 2000), and was 
later found to be associated with other types of 
cancer with epithelial or endodermal origins. 
Moreover, elevated expression of SERPINB3 is 
associated with high-grade breast carcinoma and 
correlates with estrogen receptor/progesterone 
receptor double negative tumors as well as with a 
poor prognosis for breast cancer patients (Catanzaro 
et al., 2011). 
Localisation 
SERPINB3 may be found in cytoplasmic and 
pericellular locations (Uemura et al., 2000). 
Moreover an additional surface localization for this 
serpin has been reported (De Falco et al., 2001; 
Vidalino et al., 2012). 
Although it was initially reported that SERPINB3 is 
a cytosolic protein, its nuclear localization has been 
also described recently, expanding the potential 
range of physiological functions of this molecule. 
Under certain conditions, such as following 
exposure to UV irradiation, SERPINB3 is 
translocated into the nucleus. Although SERPINB3 
does not possess a nuclear localization signal, it 
binds with c-Jun NH2-terminal kinase-1 (JNK1), 
and upon JNK1 activation SERPINB3 enters the 
nucleus (Katagiri et al., 2006). 
In addition, other studies have shown that 
SERPINB3 may be secreted in serum and can 
predict HCC development in patients with cirrhosis 
(Pontisso et al., 2006). 
Function 
SERPINB3 is physiologically involved in the 
regulation of differentiation in normal squamous 
epithelium and is overexpressed in neoplastic tissue 
of epithelial origin, where it might be involved in 
the apoptotic pathway as a protease inhibitor 
(Suminami et al., 1998). 
Regarding their role in normal epithelia, it has been 
suggested that SCCA isoforms may protect from 
bacterial, viral cystein proteases (Suminami et al., 
1998), and mast cell chymase (Schick et al., 1997). 
As a protease inhibitor, SERPINB3 is able to 
inhibit cysteine proteases (cathepsins L, S, K and 
papain) (Schick et al., 1998), and in cancer cells it 
confers resistance to drug-induced apoptosis by 
inhibiting lysosomal cathepsin proteases (Suminami 
et al., 2000). However, under a variety of stress 
conditions SERPINB3 displays an anti-apoptotic 
function unrelated to its proteinase inhibition 
activity (Vidalino et al., 2009; Ciscato et al., 2014). 
Indeed, SERPINB3 protects cells from exposure to 
radiation through an inhibitory effect either on the 
MAP family of c-Jun terminal kinase (JNK) 
(Katagiri et al., 2006) and the interaction between 
SERPINB3 and JNK1 was also supported by the 
crystallographic study (Zheng et al., 2009); or with 
a decreased phosphorylation of the proapoptotic 
p38 mitogen-activated protein kinase on p38 
(Murakami et al., 2001). In epithelial ovarian 
cancer cells exposed to cisplatin, SERPINB3 
expression is associated with drug resistance and 
poor progression-free survival (Ullman et al., 2011; 
Lim et al., 2012), whereas it inhibits the release of 
mitochondrial cytochrome c in squamous cell 
carcinoma after treatment with TNF-α (Hashimoto 
et al., 2005), or with DNA alkylating agents 
(Ullman et al., 2011). 
Moreover, SERPINB3 expression is associated with 
poor survival in patients with breast cancer treated 
with anthracycline-based neoadjuvant 
chemotherapy (Collie-Duguid et al., 2012) and in 
patients with epithelial ovarian cancer a high 
SERPINB3 expression is a prognostic factor for 
platinum resistance and shorter progression-free 
survival (Lim et al., 2012). 
In addition, recent results, reported that SERPINB3 
protects from oxidative damage by 
chemotherapeutics through inhibition of 
mitochondrial respiratory complex I (Ciscato et al., 
2014). 
Experiments carried out with serum-derived HBV 
particles have demonstrated that isolated 
SERPINB3 protein is able to bind preS1 encoded 
sequence HBV surface protein, allowing virus entry 
into human hepatocytes and also peripheral blood 
mononuclear cells, underlying its potential 
biological role in HBV infection (De Falco et al., 
2001; Pontisso et al., 1991; Ruvoletto et al., 2004). 
This serpin induces also cell proliferation and 
deregulation of adhesion processes, leading to 
epithelial-mesenchymal transition (EMT) with 
increased invasiveness potential (Quarta et al., 
2010). In addition, it has been reported that it 
induces TGF-β expression (Calabrese et al., 2008; 
Turato et al., 2010) and promotes fibrogenesis in 
experimental models (Lunardi et al., 2011). 
In addition, SERPINB3 may enhance its oncogenic 
potential through inhibition of several tumor 
suppressive miRNAs (Turato et al., 2014a) and 
could play a role in the development of cancer 
phenotype. 
More recently, it has been reported that increased 
SERPINB3 expression leads to inhibition of protein 
turnover, unfolded protein response, activation of 
NF-kB and is essential for Ras-mediated cytokine 
production and tumour growth (Catanzaro et al., 
2014). 
Homology 
SERPINB3 and SERPINB4 isoforms, also known 
as squamous cell carcinoma antigen 1 and 2 
SERPINB3 (serpin peptidase inhibitor, clade B (ovalbumin), 
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(SCCA1 and SCCA2) are highly homologous, 91% 
identical at the amino acid level (Suminami et al., 
1991), share conserved tertiary structure, and use a 
unique conformational rearrangement for their 
inhibitory activity (Stein et al., 1990).  
However, SERPINB3 and SERPINB4 show distinct 
properties and substrates: SERPINB3 inhibits 
papain-like cysteine proteinases, cathepsins K, L, 
and S while SCCA2 inhibits chymotrypsin-like 
serine proteinases, cathepsin G and mast cell 
chymase (Takeda et al., 1995; Schick et al., 1997). 
In mouse, SCCA locus (SERPINB3 and 
SERPINB4) was expanded and contained four 
genes, Serpinb3a, -b3b, -b3c, and -b3d, and three 
pseudogenes, Serpinb3-ps1, -ps-2, and -ps-3. 
Percentage protein sequences identity: 55-59%) 
(Askew et al., 2004). 
Moreover similarity-to-human data found for 
SERPINB3 was found in: worm (Caenorhabditis 
elegans), fruit fly (Drosophila melanogaster), 
mosquito (Anopheles gambiae), chicken (Gallus 
gallus), mouse (Mus musculus), rattus (Rattus 
norvegicus) and chimpanzee (Pan troglodytes). 
Mutations 
Note 
Maps of different Single-nucleotide polymorphisms 
(SNP) in human SERPINB3 are reported in Fig.2. 
Only SNP rs3180227 has beeen well characterised 
(Turato et al., 2009).  
This polymorphic variant (also know as SCCA-PD) 
presents the 351G/A mutation in the variable 
reactive site loop (RSL) of the protein (GenBank 
accession number: AY190327). 
The prevalence of SCCA-PD was 24% in the 
normal population, while in patients with cirrhosis 
it was 45%, supporting the hypothesis of a higher 
contribution of this isoform to liver disease 
progression.  
In addition, the specific amino acid change detected 
in the reactive center of this SNP might confer a 
different biological behavior to the serpin 
improving the antiprotease activity of SERPINB3 




Several papers have documented the key role of 
SERPINB3 in Hepatocellular Carcinoma (HCC). 
SERPINB3 is almost undetectable in normal liver 
but it is expressed in HCC cells and in cells of 
highly dysplastic nodules and hepatocytes of peri-
tumoral cirrhotic tissue, suggesting that SERPINB3 
expression may represent a relatively early event in 
hepatocarcinogenesis (Guido et al., 2008). 
SERPINB3 has been proposed as a serological 
biomarker that, alone or in combination with α-
fetoprotein, may improve the sensitivity of HCC 
diagnosis (Beneduce et al., 2005; Giannelli et al., 
2007a).  
Circulating SERPINB3-IgM immuno-complexes 
have been described in cirrhotic patients at higher 
risk of HCC development (Pontisso et al., 2006) 
and in patients with HCC diagnosis (Beneduce et 
al., 2005). 
Moreover, it has been reported that human 
hepatoma cells, stably transfected in order to over-
express SERPINB3, exhibited a significant increase 
in proliferation rate and unequivocal evidence of 
invasiveness and Epithelial to Mesenchimal 
Transition, then potentially acting as a putative 
paracrine mediator able to favor cancer cell growth 
and metastatic invasiveness (Quarta et al., 2010). 
In addition a very recent study revealed that high 
levels of SERPINB3 were detectable in 22% of 
HCCs specimens from cirrhotic patients and were 
found to be significantly associated with early 
tumor recurrence, then representing a candidate 
prognostic marker able to identify the subset of 
most aggressive HCCs (Turato et al., 2014b). 
Lung cancer 
Note 
Elevated levels of Squamous cell carcinoma antigen 
(SCC-Ag) is secreted by non-small cell lung 
tumours (NSCLC) and can be detected in serum 
(Mino et al., 1988). 
It has been reported that preoperative SCC-Ag level 
in serum and its postoperative decrease have 
prognostic significance in NSCLC 
(Vassilakopoulos et al., 2001). 
Moreover, in another study, tumor transcriptome 
analysis has revealed the predictive and prognostic 
impact of lysosomal protease inhibitors 
(SERPINB3 and cystatin C) with clinical response 
in platinum-based chemotherapy - treated in 
NSCLC patients (Petty et al., 2006). These 




In a model of human epithelial ovarian cancer 
(EOC) using chickens, the most relevant animal 
model, SERPINB3 mRNA was induced in 
cancerous, but not normal ovaries, and it was 
abundant only in the glandular epithelium of 
cancerous ovaries of chickens. 
In addition, strong expression of SERPINB3 
protein was reported as prognostic factor for 
platinum drug resistance and for poor progression-
free survival in patients with EOC (Lim et al., 
2012). 
SERPINB3 (serpin peptidase inhibitor, clade B (ovalbumin), 
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Breast cancer 
Note 
Elevated expression of SERPINB3 is associated 
with both high grade and advanced stage human 
breast carcinomas. In addition, it has been reported 
that SCCA-positive breast tumors have a worse 
clinical outcome, including decreased overall 
survival and recurrence free survival (Catanzaro et 
al., 2011). 
Furthermore, SERPINB3 positivity predicted poor 
survival in patients treated with anthracycline-based 
chemotherapy (Collie-Duguid et al., 2012).  
The implication of SERPINB3 in breast cancer may 
provide a novel diagnostic approach that will help 
to understand the initiation and advancement of 
breast cancer and provide new therapeutic options. 
Hepatoblastoma 
Note 
Hepatoblastoma (HB) is the most common liver 
malignancy in early childhood and it is considered 
an embryonal tumour of the liver. 
According to a recent paper, SERPINB3 was 
overexpressed in 79% of the cases of HBs. 
Moreover, by immunohistochemistry SERPINB3 
expression was found mainly in the embryonic, 
blastemal, small cell undifferentiated (SCUD) 
components of HB. High SERPINB3 reactivity was 
also detected in neoplastic cell clusters of portal 
vein tumour thrombosis. Furthermore a direct 
correlation was observed between SERPINB3 gene 
expression and tumour extension, suggesting that 
this serpin might help in defining the risk profile of 




Alteration in serpin function was shown to 
associate with deregulation of cell survival as well 
as with some autoimmune traits, meaning that 
people carrying serpin dysfunction often display an 
altered immune response. A recent study explored 
SERPINB3 expression in patients with impaired 
immune response to assess the potential 
involvement of SERPINB3 in the deregulation of 
B-cell reactivity. 
Although serpins mainly act at the intracellular 
level, membrane-bound expression of SERPINB3 
was recently demonstrated also on peripheral blood 
mononuclear cells, especially on CD27+ B cells. 
Interestingly, SERPINB3 was found to be absent on 
autoimmune diseases as SLE (systemic lupus 
erythematosus) CD27+ B lymphocytes, consistent 
with its expression being suppressed by high levels 
of type I interferon, which is a typical finding in 
SLE (Vidalino et al., 2012). 
Since SERPINB3 displays an antiapoptotic 
behavior, alterations in its expression might 
contribute to the apoptotic deregulation seen in 
SLE, thereby increasing the autoantigen burden 
(Vidalino et al., 2009).  
Then, SERPINB3 expression and CD27 positivity 
were found to be directly related, suggesting that 
this serpin might also be implicated in normal B 
cell activation.  
It has to be noted that the peripheral B cell 
repertoire and particularly CD27+ B cell number is 
heterogeneously altered in SLE (Korganow et al., 
2010). 
In summary, these results may suggest a role for 
SERPINB3 in maintaining immune homeostasis, 
and that the impairment in serpin function may 




Idiopathic pulmonary fibrosis (IPF), with its 
histopathological signature of usual interstitial 
pneumonia is a chronic progressive disorder of 
interstitial lung disease of unknown etiology with a 
poor prognosis. 
It has been reported overexpression of SERPINB3 
in lung tissue of IPF patients compared with other 
forms of interstitial lung diseases and normal lungs. 
In IPF, SERPINB3 was abnormally secreted by 
metaplastic epithelial cells other than bronchial 
cells where it is normally expressed (Calabrese et 
al., 2008). 
Moreover, mice transgenic for human SERPINB3, 
showed higher TGF-β expression and more 
extended pulmonary fibrosis than controls (Lunardi 
et al., 2011).  
In addition, it has been reported that SERPINB3 
immunocomplexed is increased in scleroderma 
patients with lung fibrosis (Giannelli et al., 2007b). 
Cholesteatoma 
Note 
Cholesteatoma is a destructive and expanding 
growth consisting of keratinizing squamous 
epithelium in the middle ear and/or mastoid 
process. 
Recent data suggest that SERPINB3, STAT3, 
cathepsin K, and cathepsin L are associated with the 
proliferation and growth of cholesteatoma and that 
these proteins may be influential factors in 
cholesteatoma growth (Ho et al., 2012). 
Skin disease 
Note 
Many intrinsic and extrinsic factors are associated 
with the stratum corneum (SC) barrier disruption. 
In the study of Katagiri C, it has been reported a 
high correlation between SERPINB3 and 
transepidermal water loss (TEWL). This finding 
was confirmed by means of a barrier disruption 
SERPINB3 (serpin peptidase inhibitor, clade B (ovalbumin), 
member 3) 
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study with a topical oleic acid treatment: subjects 
with high levels of SERPINB3 readily developed 
impaired SC barrier function. Furthermore, 
SERPINB3 content showed a very high correlation 
with the number of parakeratotic cells in the 
cornified layer of the skin. These findings indicate 
that SERPINB3 can be considered a marker of 
parakeratosis and may play an inhibitory role in the 
process of nuclear digestion (Katagiri et al., 2010). 
Psoriatic Skin 
It has been also reported that Cathepsin L (a target 
of SERPINB3) is one of the lysosomal acid 
proteinases recently identified in psoriatic 
epidermis (Kawada et al., 1997) together with 
various proteinases including tryptase, chymase, 
and cathepsin G (targets of SERPINB4: see 
homology in previous paragraph) released by 
degranulation in psoriatic lesion (Harvima et al., 
1993). 
Takeda A, et al., have shown that SERPINB3/4 
isoforms (SERPINB3 and SERPINB4) are indeed 
predominantly present along the periphery of the 
intercellular space in the upper spinous cell layer of 
psoriatic epidermis from patients with a high serum 
SERPINB3/4 level. In addition, SERPINB3/4 
immunoreactivity was detected around the 
degranulated cells near the dermo-epidermal 
junction as well as in the granules of filtrated cells. 
Furthermore, strong positive staining for 
SERPINB3/4 was also found in nuclei of granular 
layer cells and a considerable number of cells in the 
elongated rete rete ridges of psoriatic epidermis. In 
particular, SERPINB3 mRNA was ubiquitously 
expressed in all normal skin, and significantly 
overexpressed in psoriatic skin tissues. On the other 
hand, SERPINB4 mRNA expression was specific 
for psoriatic skin tissues, while it was absent in 
normal epidermis (Takeda et al., 2002) 
Asthma related pathology 
Note 
A protective role of SERPINB3 in asthma was 
initially suggested by a microarray analysis of 
human bronchial epithelial cell cultures after 
stimulation with IL-4 and IL-13 (Hansel and Diette, 
2007). This serpin may exert its protective role by 
inhibiting endogenous proteases associated with the 
inflammatory response. 
Further studies indicated that SERPINB3 serum 
levels were increased in patients with bronchial 
asthma, asthma exacerbation and in patients with 
allergic rhinitis (Izuhara, 2003; Nishi et al., 2005; 
Suzuki et al., 2010). 
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